Veracyte
NASDAQ: VCYTSouth San Francisco, US · Incorporated in Delaware · 2 known investors
Veracyte develops genomic diagnostic tests for cancer, offering laboratory developed tests for thyroid, prostate, bladder, and breast cancers performed in its CLIA-certified, high-complexity labs. Its tests analyze each patient's tumor biology to help clinicians make personalized treatment decisions.
BiotechHealthtechMedical Devices
Founders & leadership
JB
Julie BrooksNamed on SEC filing
SD
Samuel D. ColellaNamed on SEC filing
SD
Shelly D. GuyerNamed on SEC filing
FE
Fred E. CohenNamed on SEC filing
BG
Brian G. AtwoodNamed on SEC filing
EJ
Evan JonesNamed on SEC filing
BH
Brook H. ByersNamed on SEC filing
JI
Jesse I. TreuNamed on SEC filing
KE
Karin EasthamNamed on SEC filing
BH
Bonnie H. AndersonNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$12.8M disclosed across 1 round · 2014
▶$12.8MraisedSep 2014 · 6 investors · Other Health CareRule 506(b)
▶$12.8MraisedSep 2014 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Julie BrooksExecutive Officer
- Samuel D. ColellaDirector
- Shelly D. GuyerExecutive Officer
- Fred E. CohenDirector
- Brian G. AtwoodDirector
- Evan JonesDirector
- Brook H. ByersDirector
- Jesse I. TreuDirector
- Karin EasthamDirector
- Bonnie H. AndersonExecutive Officer, Director
- Offering amount
- $12.8M
- Amount sold
- $12.8M
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
How Investors May Respond To Veracyte (VCYT) Raising 2026 Revenue Guidance After Returning To Profit - Simply Wall St Newssimplywall.st · Aug 2026Veracyte (VCYT) Dropped, So What Is Behind The Latest Attention? - Simply Wall St Newssimplywall.st · Aug 2026
Veracyte posts 15% revenue surge in Q2, raises FY26 guidancescanx.trade · Jul 2026
Veracyte Q2 Earnings: $150M Revenue, Raises 2026 Guidance | VCYT Stock Newsstocktitan.net · Jul 2026Frequently asked questions
- What does Veracyte do?
- Veracyte develops genomic diagnostic tests for cancer, offering laboratory developed tests for thyroid, prostate, bladder, and breast cancers performed in its CLIA-certified, high-complexity labs. Its tests analyze each patient's tumor biology to help clinicians make personalized treatment decisions.
- Who are Veracyte's investors?
- Veracyte's investors include Catalyst Health Ventures, Kleiner Perkins.
- How much funding has Veracyte raised?
- Veracyte has disclosed $12.8M raised across 1 round.
- Where is Veracyte headquartered?
- Veracyte is headquartered in South San Francisco, US.